Sonoma Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sonoma Pharmaceuticals, Inc. (SNOA) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021
Operating Activities
Net Income-3.46-4.84-5.15-5.09-3.95
Depreciation & Amortization0.140.180.130.190.23
Deferred Income Tax0.36-0.11-0.04-0.830.00
Stock Based Compensation0.220.520.670.380.37
Change in Working Capital2.481.69-1.933.131.38
Change in Accounts Receivable0.43-0.230.001.972.61
Change in Inventory-0.390.180.00-0.10-0.07
Change in Accounts Payable0.420.20-0.860.20-0.80
Change in Other Working Capital2.010.160.230.22-0.35
Other Operating Activities0.170.160.140.220.26
Net Cash from Operating Activities-0.09-2.40-6.15-4.25-3.38
Investing Activities
Capital Expenditures-0.080.00-0.27-0.14-0.18
Sales/Maturities of Investments0.000.020.010.000.00
Other Investing Activities0.000.000.010.040.57
Net Cash from Investing Activities-0.080.00-0.26-0.100.39
Financing Activities
Debt Repayment-0.40-0.48-0.89-0.50-0.48
Common Stock Issued3.081.782.877.552.29
Common Stock Repurchased0.000.000.000.000.00
Other Financing Activities0.360.370.520.000.00
Net Cash from Financing Activities3.031.682.497.403.31
Summary
Effect of Forex Changes on Cash-0.620.030.350.130.00
Net Change in Cash2.25-0.72-3.583.050.53
Cash at Beginning of Period3.133.827.404.220.00
Cash at End of Period5.373.133.827.400.00
Free Cash Flow-0.17-2.40-6.42-4.39-3.56
Supplemental Disclosures
Interest Paid0.010.020.020.020.01
Income Taxes Paid0.000.000.000.770.94